ClinicalTrials.gg

Program

apremilast

Also written as “Apremilast”, “Apremilast 20mg” and “Apremilast 30mg”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Behcet Syndrome · Arthritis, Juvenile · COVID-19, led by 3 companies.

Furthest: phase 4, since Apr 3, 201548 company-led studies, 4 open or runningNext primary completion: Jan 10, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen464 open or runningphase 4since Apr 3, 2015Apr 2, 2007Jan 10, 2027phase 1 · NCT07908641
Boehringer Ingelheim10 open or runningphase 1since Mar 22, 2021Mar 22, 2021none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 3since Oct 10, 2023Oct 10, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 34 studies since Apr 2, 2007.

  1. Apr 25, 2019Phase 3 study in Plaque PsoriasisAmgen · NCT03930186 · 152 enrolled · Germany, Japan
  2. Aug 13, 2019Phase 2 study in PsoriasisAmgen · NCT04057937 · 90 enrolled · Japan
  3. Nov 21, 2019Phase 3 study in PsoriasisAmgen · NCT04175613 · 160 enrolled · United States, Belgium, Canada and more
  4. Aug 24, 2020Phase 3 study in Behcet SyndromeAmgen · NCT04528082 · 60 planned · France, Greece, Israel and more
  5. Oct 14, 2020Phase 3 study in COVID-19Amgen · NCT04590586 · 515 enrolled · United States, Argentina, Brazil and more
  6. Mar 16, 2021Phase 3 study in Arthritis, JuvenileAmgen · NCT04804553 · 60 planned · Belgium, France, Germany and more
  7. Mar 22, 2021Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT04811573 · 20 enrolled · Germany
  8. Dec 14, 2021Phase 3 study in PsoriasisAmgen · NCT05174065 · 176 enrolled · Japan
  9. Sep 20, 2022Phase 3 study in Plaque PsoriasisAmgen · NCT05565560 · 21 enrolled · Japan
  10. Mar 8, 2023Phase 3 study in Behcet SyndromeAmgen · NCT05767047 · 48 planned · Greece, Israel, Spain and more
  11. Oct 10, 2023Humanis Saglık Anonim Sirketi's first study: phase 3 study in PsoriasisNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06084663 · 36 enrolled · India
  12. Oct 12, 2023Phase 3 study in Plaque PsoriasisAmgen · NCT06088199 · 51 enrolled · United States
  13. Nov 3, 2023Phase 3 study in Plaque PsoriasisAmgen · NCT06122649 · 203 enrolled · China
  14. Oct 26, 2026Phase 1 study in PsoriasisAmgen · NCT07908641 · 114 planned

Ahead

  1. Jan 10, 2027Primary completion: phase 1 study in PsoriasisAmgen · NCT07908641
  2. Mar 21, 2028Primary completion: phase 3 study in Arthritis, JuvenileAmgen · NCT04804553
  3. Feb 7, 2030Primary completion: phase 3 study in Behcet SyndromeAmgen · NCT04528082
  4. Mar 17, 2036Primary completion: phase 3 study in Behcet SyndromeAmgen · NCT05767047

TargetBeta

“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
RoflumilastruleAstraZenecaphase 461
ensifentrineruleMerckphase 317
difamilastruleOtsukaphase 316
tanimilastruleChiesi Farmaceuticiphase 315

Studies

All 48 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07908641Psoriasis1Not yet recruitingAmgenJan 10, 2027114
NCT06122649Plaque Psoriasis · China3CompletedAmgenFeb 28, 2025203
NCT06088199Plaque Psoriasis · United States3CompletedAmgenAug 12, 202651
NCT06084663Psoriasis · India3CompletedHumanis Saglık Anonim SirketiFeb 25, 202336
NCT05767047Behcet Syndrome · Greece, Israel, Spain and more3RecruitingAmgenMar 17, 203648
NCT05565560Plaque Psoriasis · Japan3CompletedAmgenNov 20, 202521
NCT05174065Psoriasis · Japan3CompletedAmgenAug 19, 2023176
NCT04811573Healthy · Germany1TerminatedBoehringer IngelheimAug 18, 202120
NCT04804553Arthritis, Juvenile · Belgium, France, Germany and more3RecruitingAmgenMar 21, 202860
NCT04590586COVID-19 · United States, Argentina, Brazil and more3CompletedAmgenAug 3, 2021515
NCT04528082Behcet Syndrome · France, Greece, Israel and more3RecruitingAmgenFeb 7, 203060
NCT04175613Psoriasis · United States, Belgium, Canada and more3CompletedAmgenOct 30, 2025160
NCT04057937Psoriasis · Japan2CompletedAmgenJan 18, 202190
NCT03930186Plaque Psoriasis · Germany, Japan3CompletedAmgenMay 8, 2020152
NCT03783026Arthritis, Psoriatic · United States, Austria, Belgium and more4CompletedAmgenOct 26, 2021123
NCT03777436Psoriasis · United States, Belgium, Canada and more3CompletedAmgenSep 23, 2021289
NCT03774875Psoriasis · France, Germany, Italy and more4CompletedAmgenFeb 1, 2021277
NCT03747939Arthritis, Psoriatic · United States, Austria, Belgium and more4CompletedAmgenDec 19, 2022310
NCT03721172Psoriasis · United States, Canada3CompletedAmgenMar 6, 2020595
NCT03701763Psoriasis · United States, Belgium, Canada and more3CompletedAmgenApr 25, 2022245
NCT03123471Psoriasis · United States, Canada3CompletedAmgenAug 13, 2018303
NCT02802735Pharmacokinetics · Korea, Republic of1CompletedAmgenAug 5, 201628
NCT02777554Healthy Volunteers · United States1CompletedAmgenNov 22, 2016144
NCT02641353Healthy Volunteers · United States1CompletedAmgenFeb 27, 201634
NCT02576678Psoriasis · United States, Canada, Germany and more2CompletedAmgenSep 4, 201742
NCT02425826Parapsoriasis · United States4CompletedAmgenFeb 12, 2016221
NCT02307513Behcet Syndrome · United States, France, Germany and more3CompletedAmgenSep 25, 2017207
NCT02289417Colitis, Ulcerative · United States, Australia, Bulgaria and more2CompletedAmgenSep 25, 2017170
NCT02087943Dermatitis, Atopic · United States, Canada, Japan2CompletedAmgenOct 2015191
NCT01925768Arthritis, Psoriatic · United States, Australia, Canada and more3CompletedAmgenFeb 25, 2015219
NCT01988103Psoriasis · Japan2CompletedAmgenNov 20, 2014254
NCT01690299Psoriasis · United States, Australia, Belgium and more3CompletedAmgenJul 3, 2014250
NCT01634191Healthy Volunteer · United States1CompletedAmgenMar 1, 201236
NCT01634178Healthy Volunteer · United States1CompletedAmgenMar 1, 201246
NCT01583374Spondylitis, Ankylosing · United States, Australia, Austria and more3CompletedAmgenFeb 24, 2014490
NCT01561963Healthy Subjects · United States1CompletedAmgenApr 1, 201221
NCT01307423Arthritis, Psoriatic · United States, Australia, Belgium and more3CompletedAmgenFeb 21, 2013529
NCT01285310Arthritis, Rheumatoid · United States, Czechia, Poland and more2TerminatedAmgenFeb 21, 2012237
NCT01232283Plaque Psoriasis · United States, Austria, Canada and more3CompletedAmgenMar 15, 2012413
NCT01212770Arthritis, Psoriatic · United States, Australia, Canada and more3CompletedAmgenAug 21, 2012505
NCT01212757Arthritis, Psoriatic · United States, Belgium, Bulgaria and more3CompletedAmgenJul 26, 2012488
NCT01172938Arthritis, Psoriatic · United States, Australia, Austria and more3CompletedAmgenApr 27, 2012504
NCT00866359Behcet Syndrome · United States, Turkey2CompletedAmgenMay 1, 2012111
NCT00773734Psoriasis · United States, Canada2CompletedAmgenAug 1, 2009352
NCT00606450Psoriasis · Canada, Czechia, Germany2CompletedAmgenFeb 1, 2007260
NCT00604682Psoriasis · United States2CompletedAmgenOct 1, 200519
NCT00521339Psoriasis · United States2CompletedAmgenApr 1, 200931
NCT00456092Arthritis, Psoriatic · Belgium, Canada, Germany and more2CompletedAmgenMay 9, 2009204

How it is read

Names in the registry

  • “Apremilast”, 31 entries
  • “Apremilast 20mg”, 6 entries
  • “Apremilast 30mg”, 5 entries
  • “Apremilast (CC-10004)”, 3 entries
  • “Apremilast 30 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.